Cryoport Inc (CYRX) - Total Liabilities

Latest as of March 2026: $268.62 Million USD

Based on the latest financial reports, Cryoport Inc (CYRX) has total liabilities worth $268.62 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Cryoport Inc growing its equity to track the company's year-over-year net asset growth rate.

Cryoport Inc - Total Liabilities Trend (2004–2025)

This chart illustrates how Cryoport Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Cryoport Inc to measure how efficiently the company converts operating cash flow to free cash.

Cryoport Inc Competitors by Total Liabilities

The table below lists competitors of Cryoport Inc ranked by their total liabilities.

Company Country Total Liabilities
Mobilicom Limited Warrants
NASDAQ:MOBBW
USA $11.91 Million
Fujian MinDong Electric Power Co Ltd
SHE:000993
China CN¥981.01 Million
Zhang Xiaoquan Inc.
SHE:301055
China CN¥396.64 Million
iQIYI Inc
F:IQ8
Germany €33.37 Billion
GCM Grosvenor Inc
NASDAQ:GCMG
USA $566.50 Million
Barco NV
BR:BAR
Belgium €391.87 Million
Wuhan LinControl Automotive Electronics Co. Ltd. A
SHG:688667
China CN¥386.49 Million

Liability Composition Analysis (2004–2025)

This chart breaks down Cryoport Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CYRX stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.09 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.54 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.35 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cryoport Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cryoport Inc (2004–2025)

The table below shows the annual total liabilities of Cryoport Inc from 2004 to 2025.

Year Total Liabilities Change
2025-12-31 $262.35 Million -13.01%
2024-12-31 $301.59 Million -35.66%
2023-12-31 $468.72 Million -2.94%
2022-12-31 $482.91 Million +2.50%
2021-12-31 $471.14 Million +177.62%
2020-12-31 $169.71 Million +1669.26%
2019-12-31 $9.59 Million -46.93%
2018-12-31 $18.07 Million +660.24%
2017-12-31 $2.38 Million -2.23%
2016-12-31 $2.43 Million -1.49%
2015-12-31 $2.47 Million -18.35%
2014-12-31 $3.02 Million -24.70%
2013-12-31 $4.01 Million +5.12%
2012-12-31 $3.82 Million +53.74%
2011-12-31 $2.48 Million -51.13%
2010-12-31 $5.08 Million -10.68%
2009-12-31 $5.69 Million -3.50%
2008-12-31 $5.90 Million +112.79%
2007-12-31 $2.77 Million +18.25%
2006-12-31 $2.34 Million -4.08%
2005-12-31 $2.44 Million +8.10%
2004-12-31 $2.26 Million --

About Cryoport Inc

NASDAQ:CYRX USA Integrated Freight & Logistics
Market Cap
$762.08 Million
Market Cap Rank
#10668 Global
#2799 in USA
Share Price
$15.12
Change (1 day)
+2.79%
52-Week Range
$7.72 - $16.57
All Time High
$83.29
About

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic … Read more